comprehensive -WSS

comprehensive

author：focus 2025-10-04 06:31:54 - browse：2322

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Baltimore teen accused of firing into crowd during block party mass shooting

hotspot

WSS

Patient advocates sound warning on FDA proposal on salt intake

Baltimore teen accused of firing into crowd during block party mass shooting

Eye stem cell transplant could help restore vision in injured people

Bird flu outbreak in cows is latest avian flu curveball

Apple Watch's A

Living with Hashimoto's and celiac disease, and med school, too

leisure time

comprehensive

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Google says AlphaFold 3 can map a vast universe of biomolecules

New air purifier tech could be key to improving indoor air quality

Study: AI not yet building 'n

Dobbs anniversary: the lost opportunity of abortion as health care

ActiGraph execs on goal of drug approvals with digital endpoints

Walensky prepares to leave CDC — and Congress — behind

H5N1 communication has been strictly for the birds

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress must give Medicare recipients genetic counseling access

entertainment

FDA approves first treatment for ultra

ProMED sees offers of support, but its future remains unclear